Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ethical Oncology Science
Italy
- Ownership
- Private
- Development stage
- Other
01
Overview
Lucitanib, the lead program, demonstrated a promising response rate (~50%) in heavily pre-treated FGF-aberrant breast cancer patients and showed activity in other tumor types. The median progression-free survival was reported as 9.4 months in a subset of these patients. The safety profile was consistent with VEGF inhibitors, with common adverse events including hypertension and proteinuria.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Servier
Beyond the preview
Go deeper on Ethical Oncology Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ethical Oncology Science.